Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1973 7
1974 9
1975 7
1976 28
1977 26
1978 33
1979 26
1980 29
1981 34
1982 33
1983 50
1984 39
1985 55
1986 52
1987 47
1988 49
1989 52
1990 50
1991 43
1992 50
1993 43
1994 62
1995 53
1996 56
1997 66
1998 43
1999 70
2000 60
2001 43
2002 55
2003 54
2004 59
2005 64
2006 64
2007 77
2008 85
2009 79
2010 85
2011 93
2012 84
2013 104
2014 94
2015 106
2016 85
2017 99
2018 85
2019 82
2020 82
2021 74
2022 74
2023 64
2024 78
2025 76
2026 40

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,867 results

Results by year

Filters applied: . Clear all
Page 1
Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.
Huhn AS, Finan PH, Gamaldo CE, Hammond AS, Umbricht A, Bergeria CL, Strain EC, Dunn KE. Huhn AS, et al. Sci Transl Med. 2022 Jun 22;14(650):eabn8238. doi: 10.1126/scitranslmed.abn8238. Epub 2022 Jun 22. Sci Transl Med. 2022. PMID: 35731889 Clinical Trial.
In two-group comparisons, participants receiving suvorexant displayed increased TST during the buprenorphine/naloxone taper and decreased SOWS during the post-taper period. In three-group comparisons, participants receiving 20 mg of suvorexant versus placebo displayed incr …
In two-group comparisons, participants receiving suvorexant displayed increased TST during the buprenorphine/naloxone taper and decre …
Intranasal Naloxone Repeat Dosing Strategies and Fentanyl Overdose: A Simulation-Based Randomized Clinical Trial.
Strauss DG, Li Z, Chaturbedi A, Chakravartula S, Samieegohar M, Mann J, Nallani SC, Prentice K, Shah A, Burkhart K, Boston J, Fu YA, Dahan A, Zineh I, Florian JA. Strauss DG, et al. JAMA Netw Open. 2024 Jan 2;7(1):e2351839. doi: 10.1001/jamanetworkopen.2023.51839. JAMA Netw Open. 2024. PMID: 38261323 Free PMC article. Clinical Trial.
OBJECTIVE: To compare naloxone plasma concentrations between different intranasal naloxone repeat dosing strategies and to estimate their effect on fentanyl overdose. ...The median brain hypoxia time after a simulated fentanyl 2.97-mg intravenous bolus was 4.5 minut …
OBJECTIVE: To compare naloxone plasma concentrations between different intranasal naloxone repeat dosing strategies and to est …
Naloxone-ethanol interaction in experimental and clinical situations.
Nuotto E, Palva ES, Seppälä T. Nuotto E, et al. Acta Pharmacol Toxicol (Copenh). 1984 Apr;54(4):278-84. doi: 10.1111/j.1600-0773.1984.tb01931.x. Acta Pharmacol Toxicol (Copenh). 1984. PMID: 6375258 Clinical Trial.
The effect of naloxone on ethanol-induced impairment of psychomotor performance was studied in a series of three placebo-controlled, double-blind trials. ...Other alcohol effects were not significantly antagonized by naloxone. The clinical part of the study, consist …
The effect of naloxone on ethanol-induced impairment of psychomotor performance was studied in a series of three placebo-controlled, …
Naloxone Administration by Untrained Community Members.
Eggleston W, Calleo V, Kim M, Wojcik S. Eggleston W, et al. Pharmacotherapy. 2020 Jan;40(1):84-88. doi: 10.1002/phar.2352. Epub 2019 Dec 17. Pharmacotherapy. 2020. PMID: 31782193 Clinical Trial.
STUDY OBJECTIVE: Access to naloxone is a priority for reducing opioid deaths. Although community members who complete naloxone training are able to administer nasal naloxone successfully and rapidly, little is known about the ability of community members to a …
STUDY OBJECTIVE: Access to naloxone is a priority for reducing opioid deaths. Although community members who complete naloxone …
Spatial and neighborhood-level correlates of lay naloxone reversal events and service availability.
Yi G, Dayton L, Uzzi M, Browne K, Konstantopoulos A, Latkin C. Yi G, et al. Int J Drug Policy. 2022 Aug;106:103739. doi: 10.1016/j.drugpo.2022.103739. Epub 2022 Jun 9. Int J Drug Policy. 2022. PMID: 35691087 Clinical Trial.
This study analyzes spatial and neighborhood correlates of free naloxone distribution sites as well as overdose and naloxone reversal events in Baltimore, Maryland, which has one of the highest overdose rates in the country. ...CONCLUSION: Study findings emphasize t …
This study analyzes spatial and neighborhood correlates of free naloxone distribution sites as well as overdose and naloxone r …
Clinical trial of naloxone in birth asphyxia.
Chernick V, Manfreda J, De Booy V, Davi M, Rigatto H, Seshia M. Chernick V, et al. J Pediatr. 1988 Sep;113(3):519-25. doi: 10.1016/s0022-3476(88)80645-0. J Pediatr. 1988. PMID: 3045281 Clinical Trial.
Of 85 infants with 1-minute Apgar score 0 to 3, 44 received an injection of naloxone (approximately 0.4 mg/kg) and 41 received saline solution. In 108 infants with 1-minute Apgar score 4 to 6, 54 received naloxone and 54 saline solution. ...We conclude that nalox …
Of 85 infants with 1-minute Apgar score 0 to 3, 44 received an injection of naloxone (approximately 0.4 mg/kg) and 41 received saline …
Pharmacokinetics and Safety of Oxycodone/Naloxone Prolonged-Release Tablets in Chinese Patients with Chronic Pain.
He Y, Yang L, Mou Q, Cao X, Zhu X, Wang Y, Luo Z. He Y, et al. Drug Des Devel Ther. 2025 Jun 7;19:4933-4944. doi: 10.2147/DDDT.S486714. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40502551 Free PMC article. Clinical Trial.
Both median time to C(max) (T(max)) were 2.00 h. Parameters of naloxone and its main metabolite naloxone-3beta-D-glucuronide were C(max) 89.3 20.6 and 85.6 23.4 ng/mL, AUC(0-t) 547 104 and 538 131 h*ng/mL, AUC(0- ) 552 104 and 543 133 h*ng/mL, and t(1/2) …
Both median time to C(max) (T(max)) were 2.00 h. Parameters of naloxone and its main metabolite naloxone-3beta-D-glucuronide w …
Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
Binswanger IA, Rinehart D, Mueller SR, Narwaney KJ, Stowell M, Wagner N, Xu S, Hanratty R, Blum J, McVaney K, Glanz JM. Binswanger IA, et al. J Gen Intern Med. 2022 Aug;37(11):2624-2633. doi: 10.1007/s11606-021-07356-6. Epub 2022 Feb 7. J Gen Intern Med. 2022. PMID: 35132556 Free PMC article. Clinical Trial.
BACKGROUND: Although naloxone prevents opioid overdose deaths, few patients prescribed opioids receive naloxone, limiting its effectiveness in real-world settings. Barriers to naloxone prescribing include concerns that naloxone could increase risk beha …
BACKGROUND: Although naloxone prevents opioid overdose deaths, few patients prescribed opioids receive naloxone, limiting its …
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.
Johansson J, Hirvonen J, Lovró Z, Ekblad L, Kaasinen V, Rajasilta O, Helin S, Tuisku J, Sirén S, Pennanen M, Agrawal A, Crystal R, Vainio PJ, Alho H, Scheinin M. Johansson J, et al. Neuropsychopharmacology. 2019 Aug;44(9):1667-1673. doi: 10.1038/s41386-019-0368-x. Epub 2019 Mar 13. Neuropsychopharmacology. 2019. PMID: 30867551 Free PMC article. Clinical Trial.
Nasal spray formulations of naloxone, a mu-opioid receptor (MOR) antagonist, are currently used for the treatment of opioid overdose. ...Naloxone plasma concentrations peaked at ~20 min post naloxone, associated with slightly delayed development of brain MOR …
Nasal spray formulations of naloxone, a mu-opioid receptor (MOR) antagonist, are currently used for the treatment of opioid overdose. …
Buprenorphine and naloxone alone and in combination in opioid-dependent humans.
Preston KL, Bigelow GE, Liebson IA. Preston KL, et al. Psychopharmacology (Berl). 1988;94(4):484-90. doi: 10.1007/BF00212842. Psychopharmacology (Berl). 1988. PMID: 2453895 Clinical Trial.
Subjective, physiological and behavioral effects of subcutaneously administered hydromorphone (6 mg), naloxone (0.2 mg), buprenorphine (0.2 and 0.3 mg), and two buprenorphine-naloxone combinations (buprenorphine 0.2 mg plus naloxone 0.2 mg and buprenorphine 0 …
Subjective, physiological and behavioral effects of subcutaneously administered hydromorphone (6 mg), naloxone (0.2 mg), buprenorphin …
2,867 results